Fetal fibronectin assay may reduce management cost of preterm labour: An interval analysis [11]

Pathology

Volumn 38, Issue 5, 2006, Pages 473-474

  Musaad, Samarina M A ^a   Melson, Louise C ^a   Boswell, Ross D ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FETOPROTEIN; FIBRONECTIN;

COST BENEFIT ANALYSIS; COST CONTROL; DELIVERY; ETHNOLOGY; FEMALE; GESTATION PERIOD; GESTATIONAL AGE; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; LETTER; PREDICTIVE VALIDITY; PREMATURE LABOR; PROTEIN ANALYSIS; PROTEIN DETERMINATION;

EID: 33749182332     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020600922371     Document Type: Article

References (6)

1. Lacewood CJ, Senyei AE, Dische R, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991; 325: 669-74.
2. Peaceman AM, Andrews WW, Thorp JM, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997; 177: 13-8.
3. Greenhagen JB, Van Wagoner J, Dudley D, et al. Value of fetal fibronectin as a predictor of preterm delivery for a low-risk population. Am J Obstet Gynecol 1996; 175: 1054-6.
4. Giles W, Bisits A, Knox M, et al. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am J Obstet Gynecol 2000; 182: 439-42.
5. Lowe MP, Zimmerman B, Hansen W. Prospective randomized controlled trial of fetal fibronectin on preterm labour management in a tertiary care centre. Am J Obstet Gynecol 2004; 190: 358-62.
6. Musaad SMA, Melson CL, Boswell DR. Assessment of the impact of introducing fetal fibronectin assay in the management of preterm labour at Middlemore Hospital, New Zealand. Pathology 2005; 37: 1-5.